<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797753</url>
  </required_header>
  <id_info>
    <org_study_id>INT17470</org_study_id>
    <secondary_id>U1111-1267-9023</secondary_id>
    <nct_id>NCT05797753</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)</brief_title>
  <official_title>A Phase 1, Single-center, Open-label, 2-part, 2-treatment Period, 1-sequence, Cross-over, Drug-drug Interaction Study to Investigate the Effect of Erythromycin on SAR443820 (Part A) and the Effect of Itraconazole on SAR443820 (Part B) in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, cross-over, 2-part study for pharmacokinetic (PK) assessment of SAR443820&#xD;
      when co-administered with cytochrome P450 3A4 (CYP3A4) inhibitors (erythromycin ethyl&#xD;
      succinate (EES) in Part A and possibly itraconazole in Part B).&#xD;
&#xD;
      In Part A, the objective is to assess the effects of repeated administration of EES as CYP3A4&#xD;
      inhibitor, on the PK profile of a single oral dose of SAR443820 tablet in healthy male and&#xD;
      female participants.&#xD;
&#xD;
      In Part B, the objective is to assess the effects of repeated administration of itraconazole&#xD;
      on the PK profile of a single oral dose of SAR443820 capsule in healthy male participants.&#xD;
&#xD;
      Part A includes a screening period, Period 1 (SAR443820), a wash-out period and Period 2&#xD;
      (SAR443820 + EES). Part B includes a screening period, Period 1 (SAR443820), a wash-out&#xD;
      period and Period 2 (SAR443820 + itraconazole). The washout period between single SAR443820&#xD;
      administration in Period 1 and the start of dosing with EES (Part A) or itraconazole (Part B)&#xD;
      in Period 2 is at least 4 days.&#xD;
&#xD;
      The study duration is approximately 7 weeks for each Part A and Part B.&#xD;
&#xD;
      The treatment duration is:&#xD;
&#xD;
        -  For SAR443820 (both Part A and Part B): 1 day in each Period; single dose of SAR443830&#xD;
           on Period 1 (P1)-Day 1 and on Period 2 (P2)-Day 6 for each Part.&#xD;
&#xD;
        -  For EES (Part A): 9 days of treatment in Period 2 with P2-Day 1 starting at least 4 days&#xD;
           after P1-Day 1.&#xD;
&#xD;
        -  For itraconazole (Part B): the treatment duration lasts 11 days in Period 2 and it is&#xD;
           fixed once the results of Part A are issued, P2-Day 1 starting at least 4 days after&#xD;
           P1-Day 1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study duration was approximately 7 weeks for each Part A and Part B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2022</start_date>
  <completion_date type="Actual">July 1, 2022</completion_date>
  <primary_completion_date type="Actual">July 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: SAR443820: Area under the plasma concentration from time zero to the last concentration above the limit of quantification (AUClast)</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: SAR443820: Area under the plasma concentration (AUC)</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: SAR443820: AUClast</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: SAR443820: AUC</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: SAR443820: Maximum plasma concentration observed (Cmax)</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: SAR443820: Time to reach Cmax (tmax)</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: SAR443820: Terminal half-life (t1/2z)</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: SAR443820: Cmax</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: SAR443820: tmax</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: SAR443820: t1/2z</measure>
    <time_frame>Period 1: Day 1 to Day 3; Period 2: Day 6 to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Erythromycin ethyl succinate concentrations</measure>
    <time_frame>Period 2: Day 6 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Erythromycin base concentration</measure>
    <time_frame>Period 2: Day 6 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Itraconazole: Cmax</measure>
    <time_frame>Period 2: Day 6 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Itraconazole: AUClast</measure>
    <time_frame>Period 2: Day 6 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Hydroxyitraconazole: Cmax</measure>
    <time_frame>Period 2: Day 6 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Hydroxyitraconazole: AUClast</measure>
    <time_frame>Period 2: Day 6 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: number of participants with treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Period 1: Day 1 to Day 4; Period 2: Day 1 to Day 10 + 3 days of end of study (EOS) period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: number of participants with TEAEs</measure>
    <time_frame>Period 1: Day 1 to Day 4; Period 2: Day 1 to Day 12 + 8-10 days of end of study (EOS) period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (Healthy Volunteers)</condition>
  <arm_group>
    <arm_group_label>Part-A, Period-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SAR443820 tablet on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part-A, Period-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SAR443820 tablet on Day 6, and erythromycin ethyl succinate (EES) three-time a day (TID) from Day 1 to Day 9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part-B, Period-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SAR443820 capsule on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part-B, Period-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of SAR443820 capsule on Day 6, and Itraconazole once daily (QD) from Day 1 to Day 11</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR443820</intervention_name>
    <description>Tablet by oral administration</description>
    <arm_group_label>Part-A, Period-1</arm_group_label>
    <arm_group_label>Part-A, Period-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR443820</intervention_name>
    <description>Capsule by oral administration</description>
    <arm_group_label>Part-B, Period-1</arm_group_label>
    <arm_group_label>Part-B, Period-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin ethyl succinate</intervention_name>
    <description>Tablet by oral administration</description>
    <arm_group_label>Part-A, Period-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Capsule by oral administration</description>
    <arm_group_label>Part-B, Period-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Part A: male or female participant must be 18 to 55 years of age inclusive, at the&#xD;
             time of signing the informed consent&#xD;
&#xD;
          -  Part B: male participant only must be 18 to 55 years of age inclusive, at the time of&#xD;
             signing the informed consent&#xD;
&#xD;
          -  Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0&#xD;
             kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m^2, inclusive&#xD;
&#xD;
          -  Contraceptive use by men and women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any history or presence of clinically relevant cardiovascular, pulmonary,&#xD;
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,&#xD;
             osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or&#xD;
             infectious disease, or signs of acute illness - Any medication (including St John's&#xD;
             Wort) within 14 days before inclusion or within 5 times the elimination half-life or&#xD;
             pharmacodynamic half-life of the medication, with the exception of hormonal&#xD;
             contraception or menopausal hormone replacement therapy; any non-live Covid-19 vaccine&#xD;
             within the last 2 weeks before inclusion, any live attenuated vaccine within the last&#xD;
             28 days before inclusion and any other non-vaccine biological drugs given within 4&#xD;
             months before inclusion&#xD;
&#xD;
          -  Current enrollment in Part A (applicable for Part B) or past participation in previous&#xD;
             clinical study on SAR443820&#xD;
&#xD;
          -  Positive result for hepatitis B, C or human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Positive result on urine drug screen&#xD;
&#xD;
          -  Positive urine alcohol test&#xD;
&#xD;
          -  Any consumption of citrus fruits (grapefruit, orange, etc) or their juices within 5&#xD;
             days before inclusion The above information is not intended to contain all&#xD;
             considerations relevant to a potential participation in a clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network-Site Number:8400001</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 22, 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

